Watch More Highlights
Lisa Nodzon, PhD, ARNP, AOCNP, of the H. Lee Moffitt Cancer Center & Research Institute, discusses key information for advanced practitioners on the B-cell maturation antigen, a target for multiple myeloma, and CAR T-cell therapy, now approved for relapsed or refractory disease. Although the results have been encouraging, relapses still occur, highlighting the need to understand how best to sequence the regimen and the role of antibody-drug conjugates, bispecific antibodies, and CAR-T cells.